Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-ViVA: Low-dose AZA, ATRA, Pioglitazone vs Standard AZA in Refractory AML
NCT02942758Phase 2Terminated
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tretinoin, pioglitazone in acute myeloid leukemia (AML), sponsored by Universitätsklinikum Regensburg. Started Apr 2017; status: terminated.
02
Drugs
tretinoinpioglitazone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02942758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942758.